NMRA — Stock Film
STOCK FILMSCENE 1/11NMRA · $1.04
Stock Expert AI presents
NMRA
Neumora Therapeutics, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Neumora Therapeutics, Inc. What it actually does.

Develop novel therapeutic treatments for brain diseases. Focus on neuropsychiatric and neurodegenerative disorders. Now — the numbers.

63 employees
$192.7M market value
Revenue last year:
$0
The loss that same year:
$236.9M
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
2022
2023
2024
$0
2025
In the vault right now:
$182.5M
DEBT: $477K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
34 buy31 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
17
very weak

Clearly below the class average.

FINANCIAL STRENGTH
16
very weak

Clearly below the class average.

VALUATION
1
very weak

Clearly below the class average.

PRICE MOMENTUM
19
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 34 buys and 31 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $236.9M against $0 in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
26 / 100 · MoonshotScore

On our five-subject report card, NMRA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: NMRA is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (1/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film